Neuroinflammation-Associated Microglia represent a distinct subset of microglia that become activated in response to chronic neuroinflammation in neurodegenerative diseases. Unlike classical pro-inflammatory (M1) or anti-inflammatory (M2) microglia, this population exhibits a complex phenotype characterized by both neuroprotective and neurotoxic functions. These cells play critical roles in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions, making them important therapeutic targets. [@perry2010] The study of neuroinflammation-associated microglia has revealed remarkable heterogeneity in microglial activation states, with significant implications for understanding disease mechanisms and developing treatments. PMID: 28602351
Microglia, the resident immune cells of the central nervous system, constitute approximately 10-15% of cells in the brain. These cells originate from embryonic yolk sac progenitors and self-renew throughout life with minimal contribution from bone marrow-derived monocytes under normal conditions. In neurodegenerative diseases, however, the boundaries between microglia and peripheral monocytes become less distinct, with circulating immune cells contributing to the neuroinflammatory response. Understanding the specific roles of neuroinflammation-associated microglia versus infiltrating monocytes is crucial for developing targeted therapeutic strategies. [@heneka2013]
Neuroinflammation-Associated Microglia represent a distinct subset of microglia that become activated in response to chronic neuroinflammation in neurodegenerative diseases. Unlike classical pro-inflammatory (M1) or anti-inflammatory (M2) microglia, this population exhibits a complex phenotype characterized by both neuroprotective and neurotoxic functions. These cells play critical roles in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions, making them important therapeutic targets. [@perry2010] The study of neuroinflammation-associated microglia has revealed remarkable heterogeneity in microglial activation states, with significant implications for understanding disease mechanisms and developing treatments. PMID: 28602351
Microglia, the resident immune cells of the central nervous system, constitute approximately 10-15% of cells in the brain. These cells originate from embryonic yolk sac progenitors and self-renew throughout life with minimal contribution from bone marrow-derived monocytes under normal conditions. In neurodegenerative diseases, however, the boundaries between microglia and peripheral monocytes become less distinct, with circulating immune cells contributing to the neuroinflammatory response. Understanding the specific roles of neuroinflammation-associated microglia versus infiltrating monocytes is crucial for developing targeted therapeutic strategies. [@heneka2013]
Microglial activation in neuroinflammation encompasses a spectrum of functional states that extend far beyond the traditional M1/M2 binary classification:
Surveilling Microglia: The baseline state characterized by highly ramified morphology, continuous process motility, and monitoring of the neural environment. These cells perform essential homeostatic functions including synaptic remodeling, clearance of cellular debris, and immune surveillance.
Activated Microglia: Upregulate major histocompatibility complex (MHC) molecules and produce inflammatory mediators in response to pathological stimuli. The nature of the activation stimulus determines the specific functional phenotype adopted.
Neuroinflammation-Associated Microglia: A distinct population that emerges in chronic neurodegenerative conditions. These cells exhibit unique transcriptional signatures characterized by upregulation of disease-associated genes including APOE, TYROBP, and complement components while downregulating homeostatic markers. This state overlaps significantly with disease-associated microglia (DAM) but emphasizes the neuroinflammatory aspects of microglial activation. [@colonna2020]
Neuroinflammation-associated microglia express a characteristic combination of markers:
| Marker | Expression | Significance |
|--------|------------|--------------|
| CD68 | High | Phagocytic marker, indicates increased phagocytic activity |
| IBA1 (AIF1) | High | Calcium-binding protein, general microglial marker |
| TREM2 | High | Triggering receptor for lipid sensing and phagocytosis |
| APOE | High | Apolipoprotein involved in lipid transport and Aβ metabolism |
| TYROBP | High | Adaptor protein for TREM2 signaling |
| CST3 | High | Cystatin C, upregulated in activated microglia |
| C1Q | Elevated | Complement component involved in synaptic pruning |
| IL-1β | Variable | Pro-inflammatory cytokine, elevated in active neuroinflammation |
| TNF-α | Variable | Pro-inflammatory cytokine |
| ARG1 | Low (typically) | Marker for alternative activation, often reduced |
Microglial activation states vary across brain regions in neurodegenerative diseases. In AD, hippocampus and entorhinal cortex show particularly pronounced microglial activation, consistent with the regional vulnerability in this disease. The substantia nigra in PD exhibits prominent microglial activation surrounding dopaminergic neurons, contributing to the progressive loss of these cells. [@masuda2022]
Neuroinflammation-associated microglia in AD respond to amyloid-beta (Aβ) plaques through multiple mechanisms:
Plaque Surrounding: Activated microglia cluster around amyloid plaques, attempting to contain and clear the pathological protein. This creates a characteristic "plaque-associated" microglial phenotype with enhanced phagocytic capacity but also increased inflammatory cytokine production.
Aβ Clearance: Through TREM2-dependent mechanisms, microglia can internalize and degrade Aβ. However, this clearance capacity becomes overwhelmed in established AD, leading to accumulation of Aβ in microglial lysosomes.
Inflammatory Cascade: Aβ activates microglia through multiple pattern recognition receptors including TLRs, CD36, and TREM2, triggering production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. This chronic inflammation contributes to neuronal dysfunction and synaptic loss. [@holtzman2024]
The relationship between microglia and tau pathology is bidirectional:
Tau-Induced Activation: Pathological tau species activate microglia, triggering inflammatory responses that contribute to disease progression.
Microglia-Mediated Spread: Microglial uptake of extracellular tau may facilitate the spread of pathology throughout the brain through a prion-like mechanism.
Clearance Functions: Some evidence suggests microglia can clear pathological tau, though this capacity appears limited in established disease.
Neuroinflammation-associated microglia exhibit enhanced synaptic pruning through complement-mediated mechanisms:
C1Q Upregulation: The complement component C1q tags synapses for elimination by microglia.
C3 Expression: Microglial C3 receptor mediates phagocytosis of C1q-tagged synapses.
Synaptic Loss Correlation: The degree of microglial activation correlates with synaptic loss in AD brains, suggesting a causal relationship.
This synaptic pruning function represents one of the most significant detrimental effects of chronic microglial activation in AD, contributing to the cognitive decline that characterizes the disease. [@zhao2024]
In PD, neuroinflammation-associated microglia accumulate in the substantia nigra pars compacta, where dopaminergic neurons are progressively lost:
Neuronal Loss Association: The density of activated microglia correlates with the degree of dopaminergic neuron loss in post-mortem studies. This spatial relationship suggests a direct role for microglia in neuronal demise.
Pro-inflammatory Mediators: Microglia in PD produce inflammatory cytokines including IL-1β, TNF-α, and IL-6, which are directly toxic to dopaminergic neurons. These mediators activate apoptotic pathways and impair mitochondrial function.
Oxidative Stress: Activated microglia generate reactive oxygen species (ROS) through NADPH oxidase activation, contributing to oxidative damage in dopaminergic neurons. The substantia nigra is particularly vulnerable to oxidative stress due to its high metabolic demands and iron content.
Glial Cell Line-Derived Neurotrophic Factor (GDNF): Interestingly, microglia can also produce neuroprotective factors including GDNF, suggesting potential dual roles in PD pathogenesis.
The pathological protein alpha-synuclein triggers microglial activation through multiple pathways:
TLR2/TLR4 Recognition: Alpha-synuclein aggregates are recognized by toll-like receptors, triggering inflammatory responses through MyD88-dependent signaling pathways.
TREM2 Activation: TREM2 can bind alpha-synuclein, leading to microglial activation and phagocytosis. Genetic variants in TREM2 influence PD risk and progression.
Propagation Mechanism: Microglial uptake and transport of alpha-synuclein may facilitate the spread of pathology throughout the brain through a prion-like mechanism, contributing to disease progression.
Microglial activation in PD extends beyond motor symptoms to affect non-motor manifestations:
Cognitive Impairment: Microglial activation in cortical regions contributes to the development of PD-related dementia, which affects up to 80% of patients with long disease duration.
Depression: Neuroinflammation has been implicated in the high rates of depression in PD patients, with cytokine levels correlating with depressive symptoms.
Sleep Disorders: Including REM sleep behavior disorder (RBD), which may precede motor symptoms by years. Microglial activation in brainstem regions regulating sleep-wake cycles contributes to these disturbances. PMID: 33516818
Autonomic Dysfunction: Microglia in autonomic centers may contribute to gastrointestinal symptoms, orthostatic hypotension, and other autonomic manifestations of PD.
Recent research has identified a specific "pro-degenerative" microglial phenotype in PD characterized by:
Disease-Associated Microglia (DAM): Similar to AD, PD brains harbor microglia with DAM-like transcriptional signatures, including APOE, TYROBP, and ITGAX upregulation.
Oxidative Stress Response: Enhanced expression of NADPH oxidase subunits and antioxidant response genes.
Iron Handling: Dysregulated iron metabolism in PD microglia contributes to oxidative stress and neuronal damage. [@wang2023]
In ALS, neuroinflammation-associated microglia contribute to motor neuron degeneration:
Temporal Pattern: Microglial activation increases with disease progression, with maximal activation in symptomatic stages.
Dual Roles: Microglia may have both beneficial (clearing debris, supporting neurons) and harmful (producing inflammatory cytokines, eliminating synapses) functions.
TREM2 Involvement: TREM2 variants influence ALS progression, suggesting microglial activation state modifies disease course.
SOD1 Models: In transgenic SOD1 mouse models, microglia transition from neuroprotective to neurotoxic phenotypes as disease progresses.
Although primarily considered an autoimmune demyelinating disease, MS involves significant microglial activation:
Acute Lesions: Highly activated microglia in active demyelinating lesions produce inflammatory cytokines and mediate myelin phagocytosis.
Chronic Lesions: In chronic lesions, microglia adopt a more dystrophic phenotype with limited inflammatory capacity.
Progressive MS: In progressive forms, microglia in normal-appearing white matter show chronic activation, contributing to axonal loss and disease progression.
Microglial activation is observed throughout HD progression:
Early Activation: Microglial activation occurs before manifest symptoms, suggesting a role in disease initiation.
Correlates with Pathology: The degree of microglial activation correlates with striatal degeneration and disease severity.
Mutant Huntingtin Effects: Microglia bearing mutant huntingtin show altered inflammatory responses that may contribute to neurodegeneration.
FTD involves microglial activation driven by multiple pathological proteins:
TDP-43 Pathology: The majority of FTD cases feature TDP-43 pathology, which triggers microglial activation.
Tau Pathology: In FTD with tauopathy, microglia respond to tau aggregates in a manner similar to AD.
Genetic Links: Microglial risk genes including TREM2 variants modify FTD risk and progression.
Microglia undergo significant changes with aging that affect their response to neurodegeneration:
Morphological Changes: Aging microglia show beaded processes, reduced process complexity, and increased soma size.
Transcriptional Reprogramming: Aging microglia upregulate inflammatory genes while downregulating homeostatic markers, a state termed "inflammaging."
Impaired Surveillance: Aged microglia show reduced process motility and slower response to injury.
Decreased Clearance: Age-related decline in phagocytic capacity impairs clearance of pathological proteins and cellular debris.
Senescent microglia accumulate in aging and neurodegenerative brains:
Senescence-Associated Secretory Phenotype (SASP): Senescent microglia secrete pro-inflammatory cytokines, chemokines, and proteases that propagate inflammation.
DNA Damage: Accumulated DNA damage triggers microglial senescence through p53 and p21 pathways.
Mitochondrial Dysfunction: Impaired mitochondrial function contributes to cellular stress and senescence.
Therapeutic Implications: Clearing senescent microglia (senolytics) or modulating their SASP (senostatics) represents a novel therapeutic approach. [@zhou2024]
Microglia become neuroinflammation-associated through activation of pattern recognition receptors: PMID: 31932797
Toll-Like Receptors (TLRs): TLR4 recognizes lipopolysaccharide and damaged-associated molecular patterns (DAMPs), triggering MyD88-dependent signaling and inflammatory gene expression. TLR2 recognizes components of Gram-positive bacteria and endogenous ligands released from damaged cells.
TREM2 Signaling: As discussed above, TREM2 activation drives the disease-associated microglial program through TYROBP (DAP12) adaptor protein signaling. This pathway is particularly important for amyloid and lipid sensing.
NLRP3 Inflammasome: The NLRP3 inflammasome senses cellular stress and damage, triggering caspase-1 activation and IL-1β/IL-18 production. This pathway is particularly important for chronic neuroinflammation and is a therapeutic target. [@bogoslovskiy2024]
RAGE (Receptor for Advanced Glycation Endproducts): RAGE binds advanced glycation endproducts (AGEs), Aβ, and HMGB1, activating NF-κB and contributing to inflammatory responses.
Key inflammatory pathways in neuroinflammation-associated microglia:
NF-κB Activation: The canonical inflammatory transcription factor drives expression of cytokines, chemokines, and immune-related genes. NF-κB is activated by TLR signaling, TNF-α, IL-1β, and other stimuli.
MAPK Pathways: p38 and JNK signaling contribute to inflammatory gene expression and cell stress responses. p38α in microglia is particularly important for cytokine production.
STAT Signaling: Both pro-inflammatory (STAT1) and anti-inflammatory (STAT3/STAT6) signaling operate in microglia, with the balance determining functional outcomes. STAT3 activation can limit harmful inflammation but may also suppress beneficial functions.
Cyclic GMP-AMP Synthase (cGAS)-STING Pathway: cytosolic DNA sensing through cGAS-STING triggers type I interferon responses in microglia, which may be relevant for viral infections and cellular stress. [@chen2022]
Microglial cell death pathways influence neuroinflammation:
Pyroptosis: A form of inflammatory programmed cell death mediated by gasdermin pores. In microglia, pyroptosis can be triggered by NLRP3 inflammasome activation and caspase-1 activation.
Necroptosis: Another programmed necrosis pathway that releases cellular contents and inflammatory mediators.
Apoptosis: Microglial apoptosis can occur in response to prolonged activation or specific pathological stimuli.
Understanding cell death pathways in microglia is important because the release of intracellular contents can either resolve or exacerbate neuroinflammation. [@chen2022]
Activated microglia undergo metabolic changes that support their inflammatory functions:
Glycolysis Shift: Increased glycolysis provides rapid ATP and metabolic intermediates for inflammatory processes, even in the presence of oxygen (Warburg-like effect).
Oxidative Phosphorylation: Although reduced overall, mitochondrial function continues to support cellular energetics. Mitochondrial dysfunction can lead to excessive ROS production.
Lipid Metabolism Alterations: APOE and other lipid-related genes are upregulated, reflecting changes in cellular metabolism and lipid handling. Microglial lipid metabolism is emerging as a key regulator of activation state. [@elzinga2024]
Amino Acid Metabolism: Alterations in tryptophan, arginine, and other amino acid pathways influence neurotransmitter synthesis and immune function.
Given the central role of TREM2 in microglial activation:
Agonistic Antibodies: TREM2-activating antibodies enhance microglial clustering around plaques and promote Aβ clearance. Several candidates have entered clinical trials for early AD. Results from early-phase trials show target engagement and some evidence of reduced amyloid.
Small Molecule Agonists: Oral TREM2 agonists offer an alternative to antibody-based approaches, though development is earlier in the pipeline.
Modulation of TREM2 Ligands: Strategies to increase TREM2 ligands including APOE and lipid species may enhance beneficial microglial functions. APOE isoform-specific effects are relevant here.
Gene Therapy: Viral vector delivery of TREM2 or its activators represents a longer-term therapeutic approach. [@mcdonough2024]
Reducing harmful neuroinflammation while preserving essential microglial functions:
NLRP3 Inflammasome Inhibitors: Several small molecule inhibitors are in development for inflammatory diseases and being adapted for neurodegenerative conditions. MCC950 is a potent NLRP3 inhibitor that has shown efficacy in preclinical models.
Minocycline: This antibiotic with anti-inflammatory properties has been tested in clinical trials for AD and ALS with mixed results. The broad mechanisms of action make it difficult to interpret specific effects.
TNF-α Neutralization: Anti-TNF antibodies crossing the blood-brain barrier may suppress microglial inflammation. Etanercept and other TNF inhibitors have been explored in AD.
IL-1 Receptor Antagonists: Anakinra and other IL-1 blocking agents have been tested for their potential to reduce neuroinflammation. [@bogoslovskiy2024]
Controlling microglial proliferation and survival:
CSF1R Antagonists: Reduce microglial numbers and may limit neuroinflammation in established disease. However, long-term effects of microglial depletion are not fully understood.
Selective CSF1R Modulation: Partial inhibition may reduce harmful activation while preserving essential functions.
CSF1R Agonists: Could potentially enhance beneficial microglial functions in early disease, though this approach is earlier in development. [@jurasevic2024]
Modulating microglial metabolism to shift activation states:
LXR Agonists: Enhance cholesterol efflux and may improve microglial function. LXR agonists have shown benefit in AD models but have metabolic side effects.
PPAR Agonists: Peroxisome proliferator-activated receptor agonists have anti-inflammatory effects in microglia. Pioglitazone has been tested in clinical trials for AD. PMID: 38637622
mTOR Modulation: Targeting cellular metabolism pathways can alter microglial activation states. Rapamycin and other mTOR inhibitors have shown neuroprotective effects.
Preventing excessive synaptic pruning:
C1q Inhibitors: Monoclonal antibodies against C1q are in development for preventing complement-mediated synaptic loss in AD.
C3 Inhibitors: Complement C3 inhibition may protect synapses while preserving some immune functions.
CR3 Targeting: Modulating microglial complement receptor 3 (CR3) may reduce inappropriate synaptic elimination. [@wang2023]
Microglia become neuroinflammation-associated through activation of pattern recognition receptors:
Toll-Like Receptors (TLRs): TLR4 recognizes lipopolysaccharide and damaged-associated molecular patterns (DAMPs), triggering MyD88-dependent signaling and inflammatory gene expression.
TREM2 Signaling: As discussed above, TREM2 activation drives the disease-associated microglial program through TYROBP (DAP12) adaptor protein signaling.
NLRP3 Inflammasome: The NLRP3 inflammasome senses cellular stress and damage, triggering caspase-1 activation and IL-1β/IL-18 production. This pathway is particularly important for chronic neuroinflammation. [@bogoslovskiy2024]
Key inflammatory pathways in neuroinflammation-associated microglia:
NF-κB Activation: The canonical inflammatory transcription factor drives expression of cytokines, chemokines, and immune-related genes.
MAPK Pathways: p38 and JNK signaling contribute to inflammatory gene expression and cell stress responses.
STAT Signaling: Both pro-inflammatory (STAT1) and anti-inflammatory (STAT3/STAT6) signaling operate in microglia, with the balance determining functional outcomes. [@chen2022]
Activated microglia undergo metabolic changes that support their inflammatory functions:
Glycolysis Shift: Increased glycolysis provides rapid ATP and metabolic intermediates for inflammatory processes.
Oxidative Phosphorylation: Although reduced overall, mitochondrial function continues to support cellular energetics.
Lipid Metabolism Alterations: APOE and other lipid-related genes are upregulated, reflecting changes in cellular metabolism and lipid handling. [@elzinga2024]
Given the central role of TREM2 in microglial activation:
Agonistic Antibodies: TREM2-activating antibodies enhance microglial clustering around plaques and promote Aβ clearance. Several candidates have entered clinical trials for early AD.
Small Molecule Agonists: Oral TREM2 agonists offer an alternative to antibody-based approaches, though development is earlier in the pipeline.
Modulation of TREM2 Ligands: Strategies to increase TREM2 ligands including APOE and lipid species may enhance beneficial microglial functions. [@mcdonough2024]
Reducing harmful neuroinflammation while preserving essential microglial functions:
NLRP3 Inflammasome Inhibitors: Several small molecule inhibitors are in development for inflammatory diseases and being adapted for neurodegenerative conditions.
Minocycline: This antibiotic with anti-inflammatory properties has been tested in clinical trials for AD and ALS with mixed results.
TNF-α Neutralization: Anti-TNF antibodies crossing the blood-brain barrier may suppress microglial inflammation.
Controlling microglial proliferation and survival:
CSF1R Antagonists: Reduce microglial numbers and may limit neuroinflammation in established disease.
Selective CSF1R Modulation: Partial inhibition may reduce harmful activation while preserving essential functions.
CSF1R Agonists: Could potentially enhance beneficial microglial functions in early disease. [@jurasevic2024]
Modulating microglial metabolism to shift activation states:
LXR Agonists: Enhance cholesterol efflux and may improve microglial function.
PPAR Agonists: Peroxisome proliferator-activated receptor agonists have anti-inflammatory effects in microglia.
mTOR Modulation: Targeting cellular metabolism pathways can alter microglial activation states.
sTREM2: Soluble TREM2 in CSF reflects microglial activation and is being developed as a biomarker.
YKL-40: Chitinase-3-like protein 1, a marker of neuroinflammation.
IL-6, IL-1β, TNF-α: Cytokine levels in CSF provide direct measures of inflammatory activity. PMID: 28802038
Neurofilament Light Chain (NfL): Marker of neuronal damage that correlates with neuroinflammation. [@liu2025]
TSPO PET: Translocator protein radiotracers visualize microglial activation in vivo, though specificity is limited.
CSF1R PET: Newer tracers target the colony-stimulating factor 1 receptor more specifically.
Structural MRI: Measures of brain atrophy provide indirect information about neuroinflammatory processes.
Single-Nucleus RNA-seq: Applied to post-mortem brain tissue enables characterization of microglial heterogeneity in human disease.
Single-Cell RNA-seq: From sorted cells, provides detailed transcriptional profiles of microglia in mouse models.
Spatial Transcriptomics: Techniques like Visium and MERFISH reveal the spatial organization of microglial activation in tissue sections. [@yang2025]
iPSC-Derived Microglia: Human induced pluripotent stem cells can be differentiated into microglia-like cells for disease modeling. These cells recapitulate key features of neuroinflammation-associated microglia and enable patient-specific studies. [@xie2025]
Organoid Co-Cultures: Brain organoids with integrated microglia provide more physiological disease models.
Phagocytosis Assays: Quantify Aβ, tau, or synaptic debris uptake by microglia.
Cytokine Profiling: Multiplex assays measure inflammatory mediator production.
Electrophysiology: Assess effects of microglia on neuronal function in co-culture systems.